Benzinga | Jul 14, 2021 07:09AM EDT

TransMedics FDA Advisory Committee To Review Co.'s Organ Care System Scheduled For 9:00 a.m. ET

TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted trading of the company's common stock.

The U.S. Food and Drug Administration's (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee is meeting today to review TransMedics' Organ Care System(tm) (OCS) Liver System. The OCS(tm) Liver System is a portable organ perfusion and monitoring medical device intended to preserve a donated Liver a near-physiologic, normothermic, and functioning state while continually monitoring and optimizing Liver function for eventual transplantation into the recipient.